TapImmune (NASDAQ:MRKR) Trading Down 5.4%

Share on StockTwits

Shares of TapImmune Inc. (NASDAQ:MRKR) were down 5.4% on Tuesday . The company traded as low as $2.86 and last traded at $3.00, approximately 591,276 shares traded hands during mid-day trading. An increase of 38% from the average daily volume of 427,329 shares. The stock had previously closed at $3.17.

Several brokerages have issued reports on MRKR. Nomura reissued a “buy” rating and issued a $16.00 price target on shares of TapImmune in a research note on Tuesday, August 13th. Janney Montgomery Scott cut their price target on TapImmune from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. Piper Jaffray Companies reduced their price objective on shares of TapImmune from $10.00 to $6.00 and set an “overweight” rating for the company in a research report on Wednesday, November 13th. ValuEngine upgraded shares of TapImmune from a “hold” rating to a “buy” rating in a research note on Wednesday, October 2nd. Finally, Zacks Investment Research lowered shares of TapImmune from a “hold” rating to a “sell” rating in a research note on Thursday, October 10th. One analyst has rated the stock with a sell rating, six have given a buy rating and one has issued a strong buy rating to the company. TapImmune currently has a consensus rating of “Buy” and an average price target of $10.15.

The company has a market cap of $144.93 million, a P/E ratio of -1.80 and a beta of 0.11. The stock’s 50-day moving average price is $3.64 and its 200-day moving average price is $5.35. The company has a current ratio of 15.83, a quick ratio of 15.83 and a debt-to-equity ratio of 0.01.

TapImmune (NASDAQ:MRKR) last issued its earnings results on Tuesday, November 12th. The company reported ($0.12) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.01. On average, research analysts anticipate that TapImmune Inc. will post -0.48 earnings per share for the current fiscal year.

About TapImmune (NASDAQ:MRKR)

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.

Read More: What is the Consumer Price Index (CPI)?

Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.